Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01783951

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy in Patients With Advanced Gastric Cancer

Sponsor: Capital Medical University

Conditions Gastric Cancer

Interventions Cisplatin DC-CIK S-1

Updated 7 times since 2017 Last updated: Jul 18, 2018 Started: Feb 1, 2013 Primary completion: Feb 28, 2018 Completion: Jun 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Gastric Cancer, this trial is completed. The trial is conducted by Capital Medical University and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Jan 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2017 — Jan 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Capital Medical University
Duke University
Geneplus-Beijing Co. Ltd.

Data source: Capital Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China